Covalon Technologies, an advanced medical technologies company, will showcase new wound healing and infection management products at MEDICA medical technology trade fair, 20 November to 23 November in Dusseldorf, Germany.
The latest addition to the patented ColActive family of wound care products being showcased at MEDICA is ColActive transfer, Covalon's bio-degradable wound dressing that stimulates wound healing responses in difficult to heal wounds, while allowing wound fluids to pass through the dressing.
ColActive transfer is designed to protect new-growth tissue in wounds undergoing treatment and is Food and Drug Administration approved for sale in the US. Along with the introduction of ColActive transfer, Covalon anticipates entering the nearly $500m negative pressure dressing and kit market.
Covalon CEO Brian Pedlar noted since the company announced the transformative license agreement with Molnlycke earlier November 2013, the amount of interest in its new product pipeline has spiked significantly.
"As a result, we have accelerated the unveiling of our FDA-cleared ColActiveTransfer wound dressing and our CovaCoat A.I. Anti Infective coatings.
"Along with our proven ColActive Plus wound dressings and SilverCoat Antimicrobial Foley Catheters, our strong pipeline of new products and technologies, which includes ColActive Transfer and CovaCoat A.I., positions Covalon well as a partner for wound care, urological, vascular access, surgical and orthopaedic companies and distributors," Pedlar added.
Covalon will also be unveiling its new patented CovaCoat A.I. anti infective coating technology that provides antimicrobial and anti-thrombogenic properties, without eluting antimicrobial agents from the surface of medical devices.
Covalon's CovaCoat A.I. anti infective Foley catheter significantly reduces biofilm formation on urinary catheters, the formation of which is a major source of hospital acquired infections.
The use of CovaCoat A.I. on vascular access devices provides both anti-thrombogenic and antimicrobial characteristics without the downside of delivering potentially cytotoxic antimicrobial agents directly into the bloodstream.
